| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.17 | 0.003 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.17 | 0.002 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.16 | 0.003 |
| mRNA | bid1870 | gCSI | pan-cancer | AAC | -0.12 | 0.03 |
| mRNA | BRD-K01737880 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.3 |
| mRNA | SR8278 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.4 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.094 | 0.07 |
| mRNA | R428 | CTRPv2 | pan-cancer | AAC | -0.093 | 0.03 |
| mRNA | BRD-K30748066 | CTRPv2 | pan-cancer | AAC | -0.089 | 0.4 |
| mRNA | Docetaxel | gCSI | pan-cancer | AAC | -0.079 | 0.2 |